The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Antioxidants in Central Nervous System Diseases: Preclinical Promise and Translational Challenges
Open accessAbstract
Oxidative damage is strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and stroke (brain ischemia/reperfusion injury). The availability of transgenic and toxin-inducible models of these conditions has facilitated the preclinical evaluation of putative antioxidant agents ranging from prototypic natural antioxidants such as vitamin E (alpha-tocopherol) to sophisticated synthetic free radical traps and catalytic oxidants. Literature review shows that antioxidant therapies have enjoyed general success in preclinical studies across disparate animal models, but little benefit in human intervention studies or clinical trials. Recent high-profile failures of vitamin E trials in Parkinson's disease, and nitrone therapies in stroke, have diminished enthusiasm to pursue antioxidant neuroprotectants in the clinic. The translational disappointment of antioxidants likely arises from a combination of factors including failure to understand the drug candidate's mechanism of action in relationship to human disease, and failure to conduct preclinical studies using concentration and time parameters relevant to the clinical setting. This review discusses the rationale for using antioxidants in the prophylaxis or mitigation of human neurodiseases, with a critical discussion regarding ways in which future preclinical studies may be adjusted to offer more predictive value in selecting agents for translation into human trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 2×
“Although certain vitamin E trials in AD do suggest an effect on quality-of-life parameters, such as time to enter a nursing facility [131], these studies demonstrate marginal or no benefit on deterioration of measurable brain function in persons suffering mild cognitive impairment (MCI), a prelude…”
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · cited 2×
“Neuropathology of AD arises from numerous biochemical changes such as cholinergic deficits [53]; neuronal metabolic insult (glutamate induced excitotoxicity) [99]; and oxidative stress or damage such as lipid peroxidation and protein oxidation [108].”
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074 · cited 1×
“Davis et al. and Meda et al. showed that A β /A β PP can directly induce reactive nitrogen species in cell culture models,as well as in in vivo models [7,20, 27,41,67,95,101].”
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Cited by
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
Lipid peroxidation: Physiological levels and dual biological effects
Niki, E. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.032 · Cited by 1,006
Mitochondrial Defects and Oxidative Stress in Alzheimer Disease and Parkinson Disease
Yan, M. H., Wang, X., & Zhu, X. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.014 · Cited by 718
“Therapies to remedy oxidative stress in AD and PD patients such as vitamin E, a natural antioxidant, supplementation have shown limited success in humans [201].”
BackgroundNOX Enzymes in the Central Nervous System: From Signaling to Disease
Sorce, S., & Krause, K.-H. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2578 · Cited by 471
Oxidative stress and nerve damage: Role in chemotherapy induced peripheral neuropathy
Areti, A., Yerra, V. G., Naidu, V., & Kumar, A. (2014) · Redox Biology · doi:10.1016/j.redox.2014.01.006 · Cited by 456
ROS and Brain Diseases: The Good, the Bad, and the Ugly
Popa-Wagner, A., Mitran, S., Sivanesan, S., Chang, E., & Buga, A.-M. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/963520 · Cited by 427
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub5 · Cited by 413
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Reactive Oxygen Species‐Regulating Strategies Based on Nanomaterials for Disease Treatment
Zhang, C., Wang, X., Du, J., Gu, Z., & Zhao, Y. (2021) · Advanced Science · doi:10.1002/advs.202002797 · Cited by 401
Antioxidant Therapies for Alzheimer's Disease
Feng, Y., & Wang, X. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/472932 · Cited by 379
Elevation of glutathione as a therapeutic strategy in Alzheimer disease
Pocernich, C. B., & Butterfield, D. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.003 · Cited by 346
Natural and synthetic antioxidants: An updated overview
Augustyniak, A., Bartosz, G., Čipak, A., Duburs, G., Horáková, L., Łuczaj, W., Majekova, M., Odysseos, A. D., Rackova, L., Skrzydlewska, E., et al. (2010) · Free Radical Research · doi:10.3109/10715762.2010.508495 · Cited by 319
Diet and Alzheimer’s disease risk factors or prevention: the current evidence
Solfrizzi, V., Panza, F., Frisardi, V., Seripa, D., Logroscino, G., Imbimbo, B. P., & Pilotto, A. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.56 · Cited by 297
Mitochondria and Reactive Oxygen Species: Physiology and Pathophysiology
Bolisetty, S., & Jaimes, E. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14036306 · Cited by 273
Antioxidant and bioenergetic coupling between neurons and astrocytes
Fernandez-Fernandez, S., Almeida, A., & Bolaños, J. P. (2012) · Biochemical Journal · doi:10.1042/bj20111943 · Cited by 247
White, C. L., Pistell, P. J., Purpera, M. N., Gupta, S., Fernandez-Kim, S.-O., Hise, T. L., Keller, J. N., Ingram, D. K., Morrison, C. D., & Bruce-Keller, A. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.04.002 · Cited by 245
“Oxidative stress has been implicated in neurodegenerative disease (Joseph et al., 1998), (Kamat et al., 2008), (Sayre et al., 2008), and oxidative modifications to proteins have been documented in both aging (Stadtman et al., 2003) and Alzheimer’s disease (Smith et al., 1996).”
Cumurcu, B. E., Ozyurt, H., Etikan, I., Demir, S., & Karlidag, R. (2009) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2009.02004.x · Cited by 165
Which NADPH Oxidase Isoform Is Relevant for Ischemic Stroke? The Case for Nox 2
Kahles, T., & Brandes, R. P. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4721 · Cited by 125
Vitamin E for Alzheimer's dementia and mild cognitive impairment
Farina, N., Llewellyn, D., Isaac, M. G. E. K. N., & Tabet, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002854.pub4 · Cited by 104
The role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
Raefsky, S. M., Furman, R., Milne, G., Pollock, E., Axelsen, P., Mattson, M. P., & Shchepinov, M. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.024 · Cited by 90
Mitochondrial Abnormalities in Alzheimer’s Disease
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Cardoso, S. M., & Swerdlow, R. H. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00003-9 · Cited by 86
Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms
García-Mesa, Y., Pareja-Galeano, H., Bonet-Costa, V., Revilla, S., Gómez-Cabrera, M. C., Gambini, J., Giménez-Llort, L., Cristòfol, R., Viña, J., & Sanfeliu, C. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.021 · Cited by 68
“support of such cognitive benefits for AD patients (Kamat et al., 2008; Aisen et al., 2012).”
Background
Metadata
- Authors
- Kamat, C. D., Gadal, S., Mhatre, M., Williamson, K. S., Pye, Q. N., & Hensley, K.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2008-10-24
- Volume
- 15
- Issue
- 3
- Pages
- 473-493
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2147812763
- Cited by
- 237
- References
- 39
- FWCI
- 11.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.